New Delhi, November 14, 2026 (Yes Punjab News)
The National Pharmaceutical Pricing Authority (NPPA) has extended the existing ceiling prices for orthopaedic knee implants used in knee replacement systems until January 15, 2027, providing continued price protection for patients.
The extension, announced by the Department of Pharmaceuticals, goes beyond the earlier deadline of November 15, 2026, and will remain in force unless modified through a subsequent notification.
The decision follows representations received from manufacturers and industry associations. The ceiling prices for knee implants were first notified on August 16, 2017, and have been extended periodically since then.
In a separate move, the NPPA has directed strict monitoring of Trade Margin Rationalisation (TMR) for 137 non-scheduled anti-cancer drugs, with revised prices coming into effect from November 9.
According to a statement from the Ministry of Chemicals and Fertilisers, updated price lists based on submissions received from companies up to November 11 are available on the NPPA website and through the Pharma Sahi Daam app and portal.
Manufacturers, retailers, dealers, stockists, hospitals and medical institutions have been instructed to comply with the revised prices and prominently display updated price lists at their premises and on their websites.
An official factsheet estimates that the price-control measures will generate annual savings of around Rs 3,502.31 crore for consumers, with more than 1,000 medicine brands recording significant price reductions.
As many as 76 pharmaceutical companies have reported revised maximum retail prices (MRPs) for 1,225 anti-cancer formulations covering 121 drugs.
The NPPA has also directed State Drug Controllers to closely monitor compliance across manufacturers, dealers, hospitals and medical institutions to ensure that patients receive the benefits of the revised prices.
Violations may invite overcharging proceedings under the provisions of the Drugs (Prices Control) Order, 2013.
Consumers and other stakeholders can report complaints relating to overcharging, shortages or non-availability of medicines through the Pharma Sahi Daam app or portal, the NPPA helpline at 1800-111-255, or email.
FOLLOW NOW
